NCT02448420: Study of Palbociclib and Trastuzumab With or Without Letrozole in HER2-positive Metastatic Breast Cancer

NCT02448420
Breast Cancer Type: HER2++
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Therapeutic Antibody, Serine-Threonine Kinase Inhibitor, Endocrine (Hormone) Therapy

Key Eligibility Criteria:

Gender: Female
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with untreated symptomatic brain metastases that require treatment- see trial for details
https://ClinicalTrials.gov/show/NCT02448420

Comments are closed.

Up ↑